Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr. Wallen on Technological Advances in NSCLC

March 28th 2019

Jason M. Wallen, MD, MBA, FACS, FCCP, associate professor of surgery, division chief of thoracic surgery, director of gastric and esophageal cancer program, medical director of the thoracic oncology program, Upstate University Hospital, discusses technological advances made in non–small cell lung cancer (NSCLC).

Levy Lends Insight on Promise of Checkpoint Inhibitors in SCLC

March 27th 2019

Benjamin P. Levy, MD, discusses the rise of checkpoint inhibitors in small cell lung cancer, an emerging targeted agent in non–small cell lung cancer, and the road that lies ahead in the overall landscape.

Dr. Sabari on Managing Immune-Related Adverse Events in Lung Cancer

March 27th 2019

Joshua K. Sabari, MD, assistant professor, Department of Medicine, NYU Langone’s Perlmutter Cancer Center, discusses the management of immune-related adverse events (irAEs) in patients with lung cancer.

Dr. Subramanian on the IMpower131 Trial in Squamous NSCLC

March 27th 2019

Janakiraman Subramanian, MD, medical oncologist, director of Thoracic Oncology, Center for Precision Medicine, Saint Luke’s Cancer Institute, discusses the IMpower131 trial in advanced squamous non–small cell lung cancer (NSCLC).

Dr. Perez-Soler on Improved Outlook for Patients With Lung Cancer

March 26th 2019

Roman Perez-Soler, MD, chairman of the Department of Oncology and chief of the Division of Medical Oncology at Montefiore Medical Center, discusses the improved outlook for patients with lung cancer.

Dr. Socinski on Mechanisms of Resistance in Lung Cancer

March 26th 2019

Mark A. Socinski, MD, executive medical director, AdventHealth Medical Group, discusses mechanisms of resistance in the treatment of patients with lung cancer.

Lurbinectedin Monotherapy Elicits Responses in Relapsed SCLC

March 25th 2019

Lurbinectedin as monotherapy was found to elicit responses in patients with relapsed small cell lung cancer, meeting the primary endpoint of a phase II trial by both investigator review and an independent review committee.

PD-L1 Status Central to NCCN Update for Frontline NSCLC Immunotherapy

March 23rd 2019

PD-L1 testing, while an imperfect biomarker, is the key determinant of frontline immunotherapy selection in the NCCN guidelines for non–small cell lung cancer.

Dr. Saettele on the Benefits of Using Bronchoscopies in NSCLC

March 22nd 2019

Timothy Saettele, MD, interventional pulmonologist at Saint Luke’s Hospital, discusses the benefits of using bronchoscopies in patients with non–small cell lung cancer (NSCLC).

Dr. Gubens Discusses the Role of PD-L1 in Patients With NSCLC

March 21st 2019

Matthew A. Gubens, MD, MS, discusses an update to the NCCN Guidelines regarding patients with PD-L1 non–small cell lung cancer.

Dr. Kris on Personalizing Therapy in Lung Cancer

March 20th 2019

Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses personalizing therapy in the treatment of patients with lung cancer.

Dr. Shum Discusses Dacomitinib in EGFR+ NSCLC

March 20th 2019

Elaine Shum, MD, medical oncologist, NYU Langone’s Perlmutter Cancer Center, discusses the use of dacomitinib in the treatment of patients with EGFR-positive non–small cell lung cancer.

Dr. Decker on Distinct Roles of Radiation in Lung Cancer

March 20th 2019

Roy Decker, MD, PhD, associate professor of Therapeutic Radiology, Yale Cancer Center, discusses traditional roles of radiation therapy in the treatment of patients with lung cancer.

FDA Approves Atezolizumab Regimen for Frontline Small Cell Lung Cancer

March 19th 2019

The FDA has granted an approval to the combination of atezolizumab with carboplatin and etoposide for the frontline treatment of patients with extensive-stage small cell lung cancer.

Dr. Vallieres on Postoperative QoL in Patients With Lung Cancer

March 19th 2019

Eric Vallieres, MD, medical director, Division of Thoracic Oncology, Swedish Cancer Institute, discusses postoperative quality of life in patients with lung cancer.

Dr. Jahanzeb on Immunotherapy in Oncogene-Driven NSCLC

March 19th 2019

Mohammad Jahanzeb, MD, professor of Clinical Medicine, Hematology/Oncology, Sylvester Comprehensive Cancer Center, at University of Miami Miller School of Medicine, discusses the use of immunotherapy in patients with oncogene-driven non–small cell lung cancer.

Dr. Garon on Immunotherapy in Stage III Unresectable NSCLC

March 14th 2019

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses the promise of immunotherapy in the treatment of patients with stage III unresectable non–small cell lung cancer.

Frontline Pembrolizumab Regimen Approved in Europe for Squamous NSCLC

March 14th 2019

The European Commission has approved pembrolizumab in combination with carboplatin and either paclitaxel or nab-paclitaxel for the frontline treatment of patients with metastatic squamous non–small cell lung cancer.

Dr. Wakelee on Importance of NGS Testing in NSCLC

March 12th 2019

Heather Wakelee, MD, associate professor of medicine, Stanford University Medical Center, discusses the importance of next-generation sequencing testing in the treatment of patients with non–small cell lung cancer.

Ramucirumab/Erlotinib Combo Improves PFS in Frontline EGFR+ NSCLC

March 12th 2019

The combination of ramucirumab and erlotinib significantly improved progression-free survival compared with placebo and erlotinib as a frontline treatment for patients with metastatic EGFR-mutant non–small cell lung cancer, meeting the primary endpoint of the RELAY trial (NCT02411448).